Turner Financial Group Inc. Invests $582,000 in Tempus AI, Inc. $TEM

Turner Financial Group Inc. acquired a new position in shares of Tempus AI, Inc. (NASDAQ:TEM) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 10,043 shares of the company’s stock, valued at approximately $582,000.

Several other institutional investors have also added to or reduced their stakes in the stock. Odyssean LLC acquired a new position in Tempus AI in the 2nd quarter worth $897,000. Nykredit A S acquired a new stake in shares of Tempus AI in the 2nd quarter valued at about $186,000. EMC Capital Management acquired a new stake in shares of Tempus AI in the 2nd quarter valued at about $29,000. Legacy Financial Advisors Inc. bought a new stake in shares of Tempus AI in the second quarter valued at about $235,000. Finally, Headlands Technologies LLC bought a new stake in shares of Tempus AI in the second quarter valued at about $2,689,000. 24.22% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, CEO Eric Lefkofsky sold 250,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $42.06, for a total transaction of $10,515,000.00. Following the sale, the chief executive officer owned 200,000 shares in the company, valued at $8,412,000. This represents a 55.56% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO James Rogers sold 26,313 shares of the firm’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $60.00, for a total transaction of $1,578,780.00. Following the completion of the transaction, the chief financial officer directly owned 106,024 shares of the company’s stock, valued at $6,361,440. This represents a 19.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 1,043,988 shares of company stock worth $56,963,417 over the last 90 days. Company insiders own 24.26% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on TEM shares. Cantor Fitzgerald assumed coverage on Tempus AI in a report on Wednesday. They set an “overweight” rating and a $80.00 price objective for the company. TD Cowen restated a “buy” rating on shares of Tempus AI in a research note on Wednesday, July 15th. Raymond James Financial set a $80.00 price target on Tempus AI in a research report on Wednesday. Lake Street Capital cut shares of Tempus AI to a “hold” rating in a research note on Monday, July 20th. Finally, Freedom Capital upgraded shares of Tempus AI to a “hold” rating in a report on Tuesday, June 30th. Eleven investment analysts have rated the stock with a Buy rating, five have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $68.93.

Tempus AI Price Performance

Shares of NASDAQ TEM opened at $64.62 on Friday. The stock has a market capitalization of $11.66 billion, a price-to-earnings ratio of -44.87 and a beta of 3.72. The business has a 50-day moving average of $55.77 and a 200-day moving average of $52.13. The company has a debt-to-equity ratio of 3.06, a current ratio of 3.30 and a quick ratio of 3.16. Tempus AI, Inc. has a fifty-two week low of $40.77 and a fifty-two week high of $104.32.

Tempus AI (NASDAQ:TEM) last released its earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.10. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.The business had revenue of $382.49 million for the quarter, compared to analyst estimates of $379.69 million. During the same quarter in the prior year, the company posted ($0.22) earnings per share. Tempus AI’s revenue was up 21.6% on a year-over-year basis. As a group, sell-side analysts predict that Tempus AI, Inc. will post -1.38 earnings per share for the current fiscal year.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.